Abstract
Purpose
The purpose of this study was to evaluate the effect of bevacizumab on the pharmacokinetics (PK) of irinotecan and its active metabolite. Exploratory analyses of the impact of variability in uridine diphosphate glucuronosyltransferase 1A (UGT1A) genes on irinotecan metabolism and toxicity were conducted.
Methods
This was an open-labeled, fixed-sequence study of bevacizumab with FOLFIRI (irinotecan, leucovorin, and infusional 5-fluorouracil). Pharmacokinetic assessments were conducted in cycles 1 and 3.
Results
Forty-five subjects were enrolled. No difference in dose-normalized AUC0–last for irinotecan and SN-38 between irinotecan administered alone or in combination with bevacizumab was identified. Leukopenia was associated with higher exposure to both irinotecan and SN-38. UGT1A1 polymorphisms were associated with variability in irinotecan PK. Gastrointestinal toxicity was associated with UGT1A6 genotype. No other associations between UGT1A genotypes and toxicity were detected.
Conclusion
Bevacizumab does not affect irinotecan PK when administered concurrently. A variety of pharmacogenetic relationships may influence the pharmacokinetics of irinotecan and its toxicity.
Similar content being viewed by others
References
Ando Y, Saka H, Ando M, Sawa T, Ueoka H, Yokoyama A, Saitoh S, Shimokata K, Hasegawa Y (2000) Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Can Res 60:6921–6926
Carlini LE, Meropol NJ, Chen YM, McGarry C, Hill T, Gold P, Blanchard RL (2004) Pharmacogenetic analysis of UGT1A1, UGT1A6, UGT1A7 and thymidylate synthase in a phase II study of capecitabine plus irinotecan in patients with metastatic colorectal cancer. J Clin Oncol (meeting abstracts) 22:3623
Carlini LE, Meropol NJ, Bever J, Andria ML, Hill T, Gold P, Rogatko A, Wang H, Blanchard RL (2005) UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Can Res 11:1226–1236
Chabot GG, Abigerges D, Catimel G, Culine S, de Forni M, Extra JM, Mahjoubi M, Herait P, Armand JP, Bugat R, Clavel M, Marty ME (1995) Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials. Ann Oncol 6:141–151
Common terminology criteria for adverse events version 3.0, US Department of Health and Human Services, National Institutes of Health
de Jonge MJ, Verweij J, de Bruijn P, Brouwer E, Mathijssen RH, van Alphen RJ, de Boer-Dennert MM, Vernillet L, Jacques C, Sparreboom A (2000) Pharmacokinetic, metabolic, and pharmacodynamic profiles in a dose escalating study of irinotecan and cisplatin. J Clin Oncol 18:195–203
Gagne J, Montminy V, Belanger P, Journault K, Gaucher G, Guillemette C (2002) Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). Mol Pharmacol 62:608–617
Genentech (2007) Avastin Package Insert
Guo SW, Thompson EA (1992) Performing the exact test of Hardy-Weinberg proportion for multiple alleles. Biometrics 48:361–372
Han J, Lim H, Sin ES, Yoo Y, Park YH, Lee J, Jang I, Lee DO, Lee JS (2006) Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small cell lung cancer treated with irinotecan and cisplatin. J Clin Oncol 24:2237–2244
Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New Engl J Med 350:2335–2342
Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M, Karrison T, Janisch L, Ramirez J, Rudin CM, Vokes EE, Ratain MJ (2004) Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 22:1382–1388
Innocenti F, Vokes EE, Ratain MJ (2006) Irinogenetics: what is the right star? J Clin Oncol 24:2221–2224
Iyer L, King CD, Whitington PF, Green MD, Roy SK, Thephly TR, Coffman BL, Ratain MJ (1998) Genetic predisposition to the metabolism of irinotecan (CPT-11): role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN38) in human liver microsomes. J Clin Invest 101:847–854
Iyer L, Das S, Janisch L, Wen M, Ramirez J, Karrison T, Fleming GF, Vokes EE, Schilsky RL, Ratain MJ (2002) UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2:43–47
Kehrer DFS, Sparreboom A, Verweij J, de Bruijn P, Nierop CA, van de Schraaf J, Ruijgrok EJ, de Jonge MJA (2001) Modulation of Irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients. Clin Cancer Res 7:1136–1141
Lu JF, Gaudreault J, Novotny W, Lum BL, Bruno R (2005) A population pharmacokinetic (PK) model for bevacizumab (Avastin). ASCPT meeting, Miami, Florida
Mathijssen RH, van Alphen RJ, Verweij J, Loos WJ, Nooter K, Stoter G, Sparreboom A (2001) Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Can Res 7:2182–2194
McLeod HL, Parodi L, Sargent DJ, Marsh S, Green E, Abreu P, Cisar LA, Goldberg RM (2006) UGT1A1*28, toxicity and outcome in advanced colorectal cancer: results from trial N9741. J Clin Oncol (meeting abstracts) 24:3520
Nagar S, Zalatoris JJ, Blanchard RL (2004) Human UGT1A6 pharmacogenetics: identification of a novel SNP, characterization of allele frequencies and functional analysis of recombinant allozymes in human liver tissue and in cultured cells. Pharmacogenetics 14:487–499
O’Dwyer PJ, Catalano RB (2006) Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy. J Clin Oncol 24:4534–4538
Pfizer (2007) Camptosar Package Insert
Pitot HC, Goldberg RM, Reid JM, Sloan JA, Skaff PA, Erlichman C, Rubin J, Burch PA, Adjei AA, Alberts SA, Schaaf LJ, Elfring G, Miller LL (2000) Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy. Clin Cancer Res 6:2236–2244
Poujol S, Bressolle F, Duffour J, Abderrahim AG, Astre C, Yehou M, Pinguet F (2006) Pharmacokinetics and pharmacodynamics of irinotecan and its metabolites from plasma and saliva data in patients with metastatic digestive cancer receiving folfiri regimen. Cancer Chemother Pharmacol 58:292–305
Ratain MJ (2002) Irinotecan dosing: does the CPT in CPT-11 stand for “can’t predict toxicity. J Clin Oncol 20:7–8
Rothenberg ML, Kuhn JG, Schaaf LJ, Rodriguez GI, Eckhardt SG, Villalona-Calero MA, Rinaldi DA, Hammond LA, Hodges S, Sharma A, Elfring GL, Petit RG, Locker PK, Miller LL, von Hoff DD (2001) Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks. Ann Oncol 12:1631–1641
Saeki M, Saito Y, Jinno H, Tohkin M, Kurose K, Kaniwa N, Komamura K, Ueno K, Kamakura S, Kitakaze M, Ozawa S, Sawada J (2003) Comprehensive UGT1A1 genotyping in a Japonese population by pyrosequencing. Clin Chem 49:1182–1185
Siegel S, Castellan NJ (1988) Non-parametric statistics for the behavior sciences. McGraw-Hill,
Stewart CF, Panetta JC, O’Shaughnessy MA, Throm SL, Fraga CH, Owens T, Lui T, Billups C, Rodriguez-Galindo C, Gajjar A, Furman WL, McGregor LM (2007) UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but no severe toxicity in patients receiving low-dose irinotecan. J Clin Oncol 25:2594–2600
Toffoli G, Cecchin E, Corona G, Russo A, Buonadonna A, D’Andrea M, Pasetto LM, Pessa S, Errante D, De Pangher V, Giusto M, Medici M, Gaion F, Sandri P, Galligioni E, Bonura S, Boccalon M, Biason P, Frustaci S (2006) The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 24:3061–3068
Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C, de Gramont A (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22:229–237
U.S. Department of Health and Human Services FaDA, CDER, CBER (1999) In vivo drug metabolism/drug interaction studies—study design, data analysis and recommendations for dosing and labeling. Guidance for industry, Rockville, MD
van der Bol JM, Mathijssen RH, Loos WJ, Friberg LE, van Schaik RHN, de Jonge MJ, Planting AS, Verweij J, Sparreboom A, de jonge FA (2007) Cigarette smoking and irinotecan treatment: pharmacokinetic interaction and effects on neutropenia. J Clin Oncol 25:1–8
Villeneuve L, Girard H, Fortier L, Gagne J, Guillemette C (2003) Novel functional polymorphisms in the UGT1A7 and UGT1A9 glucuronidating enzymes in Caucasian and African-American subjects and their impact on the metabolism of 7-ethyl-10-hydroxycamptothecin and flavopiridol anticancer drugs. JPET 307:117–128
Acknowledgments
We are grateful to Jacques Gaudreault and Dan Spyker for their useful input and insights into the study design. This study was supported by Genentech and Cancer Center Support Grant NCI-P30 CA 006927 to Fox Chase Cancer Center.
Conflict of interest statement
Lu Xu receives remuneration and stock ownership from Genentech. Coen Bernaards receives remuneration and stock ownership from Genentech. Andrew Dorr has a consultant/advisory role with Genentech. Julie Hambleton receives remuneration and stock ownership from Genentech. Scott Holden receives remuneration and stock ownership from Genentech. Anne Kearns receives remuneration and stock ownership from Genentech. Bert Lum receives remuneration and stock ownership from Genentech. Neal J. Meropol has a consultant/advisory role with and receives funding from Genentech. Peter J. O’Dwyer receives funding from Genentech. Crystal Denlinger, Rebecca Blanchard, Samuel Litwin, Cynthia Spittle, Daniel J. Berg, Susan McLaughlin, Maryann Redlinger, Sara Kenkare-Mitra have declared no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Additional information
N. J. Meropol and P. J. O’Dwyer contributed equally to this work.
Rights and permissions
About this article
Cite this article
Denlinger, C.S., Blanchard, R., Xu, L. et al. Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors. Cancer Chemother Pharmacol 65, 97–105 (2009). https://doi.org/10.1007/s00280-009-1008-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-009-1008-7